Metraipolis › archive › dc_29491c47f2cc

Interleukin-2 and Tretinoin for Myeloproliferative Neoplasms and to Target Type 1 Calreticulin-Driven Neoplasms: Advancements in Immune Regenerative Medicine — Europe PMC PMID:41898674

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41898674
DOI
10.3390/ijms27062814
License (as archived)
solo-consultazione
Archived
2026-11-04T04:00:50.768Z
SHA-256 of the archived text
6bfc5c0a2a5df003caa5a51c9e24fd3adb0eb3b8f46c40203a22d6aea43d2aeb
Stable URL of this page
https://metraipolis.com/documento/dc_29491c47f2cc

How to cite

Interleukin-2 and Tretinoin for Myeloproliferative Neoplasms and to Target Type 1 Calreticulin-Driven Neoplasms: Advancements in Immune Regenerative Medicine — Europe PMC PMID:41898674 — Europe PMC (en), https://europepmc.org/article/MED/41898674 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_29491c47f2cc (Metraipolis archive dc_29491c47f2cc, sha256 6bfc5c0a2a5df003caa5a51c9e24fd3adb0eb3b8f46c40203a22d6aea43d2aeb)
BibTeX
@misc{dc29491c47f2cc,
  title = {Interleukin-2 and Tretinoin for Myeloproliferative Neoplasms and to Target Type 1 Calreticulin-Driven Neoplasms: Advancements in Immune Regenerative Medicine — Europe PMC PMID:41898674},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41898674},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_29491c47f2cc; sha256 6bfc5c0a2a5df003caa5a51c9e24fd3adb0eb3b8f46c40203a22d6aea43d2aeb},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41898674. Agents can read the archived copy with the MCP tool read_document.